Clifford Chance advised Keymed Biosciences on the deal.Keymed Biosciences (HKSe: 02162) signed a licensing agreement granting Platina the exclusive worldwide rights to develop, manufacture and commercialize…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
